AVIR — Atea Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1593899 ·
Last close
$3.96
Market Cap
$318.00M
52W High
$6.45
52W Low
$2.92
ADV30
305,782
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -34,013,000 | -32,162,000 | 200,706,000 | 97,922,000 | 25,025,000 |
| Jun 2026 | 0 | — | -35,099,000 | -32,933,000 | 232,282,000 | 76,548,000 | 28,124,000 |
| Mar 2026 | 0 | — | -48,008,000 | -45,440,000 | 267,076,000 | 79,317,000 | 33,367,000 |
| Dec 2025 | 0 | — | -54,934,000 | -44,867,000 | 315,218,000 | 95,713,000 | 39,784,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-140,572,000
Investing CF
$160,698,000
Financing CF
$452,000
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.95
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-633,104,000
Inventory
—
Receivables
—
ST Investments
$93,277,000
EBIT TTM
$-172,054,000
Pretax Income TTM
$-162,058,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -180,887,000 | -158,349,000 | 315,218,000 | 39,784,000 | 275,434,000 | -132,031,000 |
| Dec 2024 | 0 | -192,950,000 | -168,385,000 | 464,668,000 | 25,801,000 | 438,867,000 | -135,499,000 |
| Dec 2023 | 0 | -164,162,000 | -135,956,000 | 594,968,000 | 39,776,000 | 555,192,000 | -85,395,000 |
| Dec 2022 | 0 | -130,650,000 | -115,909,000 | 666,708,000 | 26,136,000 | 640,572,000 | -120,982,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-165,289,000
OpCashFlow TTM
—
Assets (Latest)
$232,282,000
Forward EPS
$-1.36
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RLMD | RELMADA THERAPEUTICS, INC. | $321.15M | $3.01 | — |
| LRMR | Larimar Therapeutics, Inc. | $310.61M | $2.99 | — |
| INO | INOVIO PHARMACEUTICALS, INC. | $305.31M | $1.63 | — |
| LYEL | Lyell Immunopharma, Inc. | $336.08M | $13.67 | — |
| CTNM | Contineum Therapeutics, Inc. | $337.62M | $9.55 | — |
News headlines (Yahoo Finance, 1h cache)
Atea Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
2026-11-10 02:10 · Yahoo
Atea Pharma (AVIR) Q3 2026 Earnings Call Transcript
2026-11-10 01:00 · Yahoo
Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-09 21:05 · Yahoo
Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital
2026-11-09 12:00 · Yahoo
Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026
2026-11-02 21:05 · Yahoo
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
2026-09-08 11:00 · Yahoo
Atea (AVIR) Q2 2026 Earnings Call Transcript
2026-08-19 21:13 · Yahoo
Atea Pharmaceuticals Q2 Earnings Call Highlights
2026-08-12 22:04 · Yahoo
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
2026-08-05 11:00 · Yahoo
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial
2026-07-29 09:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.